A nationwide clinical RCT trial led by Dr. Kazumi Kimura at Kumamoto University Hospital has found that adding catheter ...

However, most people who are put on anticoagulants now use newer agents like apixaban (Eliquis) or rivaroxaban (Xarelto).

For patients with atrial fibrillation, the use of oral anticoagulant therapy to prevent stroke is limited by the risk of bleeding. Left atrial appendage closure is considered for patients who are ...

If you're taking Eliquis (apixaban) to prevent blood clots and stroke, you've likely experienced sticker shock at the ...

Anticoagulant therapy for ischaemic stroke aims to prevent recurrent ischaemic stroke and venous thromboembolism. Several large clinical trials have provided insight into the safety and efficacy of ...

Novel agent abelacimab has potential to be a safer anticoagulant, according to the randomized AZALEA-TIMI 71 trial. The trial had been stopped early because of a surprisingly large reduction in bleeds ...

Russian scientists have modified a polysaccharide (a complex carbohydrate) derived from spruce wood and enhanced its ability to prevent blood clotting and neutralise free radicals.

Anticoagulation therapy is used to prevent clot formation. They do not lyse clots but they prevent new clots from forming. Since warfarin takes time to act, heparin and warfarin are usually started ...

High discontinuation rates of OACs in NVAF patients, with 47% stopping within 120 days, highlight adherence challenges. DOACs show a lower risk of discontinuation compared to warfarin, suggesting ...

Direct oral anticoagulants (DOACs) are associated with increased prescription costs. Actual practice data show a high switch rate and poor adherence among DOAC initiators that need to be addressed.

While heparin and other blood thinners can help prevent thrombi, such anticoagulants can also disturb normal clotting ...